Ovarian Cancer - Therapy

Inhibition of Urokinase Has Potential as Treatment Modality

Published in Women's Health Weekly, September 4th, 1995

As the expression of urokinase-type plasminogen activator (uPA) is required for the spread of ovarian cancer, its subsequent inhibition may prove to be a feasible treatment modality in humans, a recent study suggests.

uPA is a protease involved in the process of cell migration and tissue remodelling. It has been found in the ascitic fluid of advanced ovarian cancer patients. It is not found in non-malignant ascitic fluid (i.e., from liver cirrhosis). Prospective clinical studies have shown that the presence of uPA in cancerous tissue extracts was a strong prognostic indicator for relapse-free and overall survival of patients with ovarian, breast or gastric...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1995-09-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry